CN102186977A - Inhbb表位肽及包含它的疫苗 - Google Patents

Inhbb表位肽及包含它的疫苗 Download PDF

Info

Publication number
CN102186977A
CN102186977A CN2009801413475A CN200980141347A CN102186977A CN 102186977 A CN102186977 A CN 102186977A CN 2009801413475 A CN2009801413475 A CN 2009801413475A CN 200980141347 A CN200980141347 A CN 200980141347A CN 102186977 A CN102186977 A CN 102186977A
Authority
CN
China
Prior art keywords
peptide
peptides
antigen
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN2009801413475A
Other languages
English (en)
Chinese (zh)
Inventor
角田卓也
大泽龙司
吉村祥子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN102186977A publication Critical patent/CN102186977A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801413475A 2008-08-19 2009-08-14 Inhbb表位肽及包含它的疫苗 Withdrawn CN102186977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8997308P 2008-08-19 2008-08-19
US61/089,973 2008-08-19
PCT/JP2009/003894 WO2010021111A1 (en) 2008-08-19 2009-08-14 Inhbb epitope peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
CN102186977A true CN102186977A (zh) 2011-09-14

Family

ID=41707002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801413475A Withdrawn CN102186977A (zh) 2008-08-19 2009-08-14 Inhbb表位肽及包含它的疫苗

Country Status (13)

Country Link
US (7) US20110280898A1 (enExample)
EP (1) EP2326718A4 (enExample)
JP (1) JP2012500001A (enExample)
KR (1) KR20110063456A (enExample)
CN (1) CN102186977A (enExample)
AU (1) AU2009283762A1 (enExample)
CA (1) CA2734515A1 (enExample)
IL (1) IL211131A0 (enExample)
MX (1) MX2011001880A (enExample)
RU (1) RU2011110504A (enExample)
SG (1) SG193214A1 (enExample)
TW (1) TW201008574A (enExample)
WO (1) WO2010021111A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104168917A (zh) * 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
CN106795204A (zh) * 2014-08-04 2017-05-31 肿瘤疗法科学股份有限公司 Urlc10衍生的肽和含有它们的疫苗

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2325305E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2009531273A (ja) * 2006-02-28 2009-09-03 オンコセラピー・サイエンス株式会社 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法
CN101432303A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗cdh3抗体的效应物功能来损伤细胞的方法
US20100009920A1 (en) * 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
WO2009016691A1 (en) * 2007-07-30 2009-02-05 Oncotherapy Science, Inc. Cancer associated gene ly6k
UA100127C2 (ru) * 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
CA2729403A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
JP5663790B2 (ja) 2008-10-22 2015-02-04 オンコセラピー・サイエンス株式会社 Ｒａｂ６ｋｉｆｌ／ｋｉｆ２０ａエピトープペプチドおよびそれを含むワクチン
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
CN104040345A (zh) * 2011-12-23 2014-09-10 医疗研究局 血管紧张素ii受体的选择性配体
EP2872531A4 (en) * 2012-07-10 2016-04-06 Oncotherapy Science Inc LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
JP6259983B2 (ja) 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
BR112015013557B1 (pt) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
RU2753512C2 (ru) * 2014-09-08 2021-08-17 Нэшнл Кэнсер Сентер Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
CA2969231C (en) 2014-12-03 2021-06-08 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7751374B2 (ja) * 2017-03-03 2025-10-08 トレオス バイオ リミテッド ペプチドワクチン
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663315A (zh) * 2007-02-21 2010-03-03 肿瘤疗法科学股份有限公司 用于表达肿瘤相关抗原的癌症的肽疫苗

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3322314C2 (de) 1983-06-21 1986-01-02 Gebhard, Dietrich, 7502 Malsch Schaltungsanordnung für ein Zugfahrzeug
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
IL103928A0 (en) 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
WO1995028484A1 (en) 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
AU6795898A (en) 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1022286A4 (en) 1997-10-07 2003-04-09 Ono Pharmaceutical Co POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
EP1103561B1 (en) 1998-07-28 2006-04-19 Green Peptide Co., Ltd. Hla-a2 restraint tumor antigen peptide originating in sart-1
WO2001064835A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
AU6280300A (en) 1999-08-04 2001-03-05 Adelbert Bacher Isoprenoid biosynthesis
AU1220001A (en) 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
MXPA02008219A (es) 2000-02-23 2005-06-30 Epimmune Inc Peptidos que enlazan hla y sus usos.
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1469926A (zh) 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6830885B1 (en) 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
US7033832B2 (en) 2000-10-13 2006-04-25 University Of Medicine And Dentistry Of New Jersey Endothelial cell—cell cohesion
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN100400099C (zh) 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
MXPA03011979A (es) 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP1487857A4 (en) 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
CA2499709A1 (en) 2002-06-19 2003-12-31 Yoichi Furukawa Method for diagnosis of colorectal tumors
EP1523577A2 (en) 2002-07-10 2005-04-20 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
FI116178B (fi) 2002-08-22 2005-09-30 Abb Oy Vaihtosuuntaajan lähtökuristinsovitelma
AU2003294217A1 (en) 2002-08-29 2004-05-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
AU2003253440A1 (en) 2002-08-30 2004-04-30 Japan As Represented By The President Of The University Of Tokyo Method of diagnosing ovarian endometriosis
CN1703524B (zh) 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
TW200413539A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003300680A1 (en) 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2004058153A2 (en) 2002-12-20 2004-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
US7337154B2 (en) 2003-05-19 2008-02-26 Raytheon Company Method for solving the binary minimization problem and a variant thereof
WO2005001138A2 (en) 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7727714B2 (en) 2003-08-20 2010-06-01 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma
EP1668354A2 (en) 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Method of diagnosing breast cancer
EP1762094A4 (en) 2003-12-08 2007-11-14 Silicon Image Inc INTEGRATED ADDRESSING SCHEME FOR USE IN A SYSTEM WITH A TREE STRUCTURE
EP1730279A2 (en) 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
WO2005090572A2 (en) 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Compositions and methods for treating pancreatic cancer
WO2005097189A1 (ja) 2004-04-09 2005-10-20 Genecare Research Institute Co., Ltd. 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
WO2006038208A2 (en) 2004-07-12 2006-04-13 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2006055371A2 (en) 2004-11-16 2006-05-26 Alexion Pharmaceuticals, Inc. Functional screening of antibody libraries
CN100381460C (zh) 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
EP2011885B1 (en) 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
EP1859266A4 (en) 2005-02-24 2010-07-28 Cemines Inc COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES
PT2325305E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
CA2599875A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
CN100348614C (zh) 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
WO2007009181A1 (en) 2005-07-20 2007-01-25 Agriculture Victoria Services Pty Ltd Modification of flavonoid biosynthesis in plants
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
JP5150909B2 (ja) 2005-07-27 2013-02-27 オンコセラピー・サイエンス株式会社 食道癌を診断する方法
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
EP1915622A2 (en) 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP4803460B2 (ja) 2005-08-09 2011-10-26 学校法人 久留米大学 Ｈｌａ−ａ２４分子結合性扁平上皮癌抗原由来ペプチド
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US20090263832A1 (en) 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
JP2009531273A (ja) 2006-02-28 2009-09-03 オンコセラピー・サイエンス株式会社 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法
CN101432303A (zh) 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗cdh3抗体的效应物功能来损伤细胞的方法
CN101467039B (zh) 2006-04-10 2013-11-06 健泰科生物技术公司 散乱蛋白pdz调节剂
US20100009920A1 (en) 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
WO2009016691A1 (en) 2007-07-30 2009-02-05 Oncotherapy Science, Inc. Cancer associated gene ly6k
UA100127C2 (ru) 2007-08-20 2012-11-26 Онкотерапи Саенс, Инк. Пептид cdh3 и лекарственное средство, содержащее его
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI543767B (zh) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2011039289A1 (de) 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663315A (zh) * 2007-02-21 2010-03-03 肿瘤疗法科学股份有限公司 用于表达肿瘤相关抗原的癌症的肽疫苗

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104168917A (zh) * 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
CN106795204A (zh) * 2014-08-04 2017-05-31 肿瘤疗法科学股份有限公司 Urlc10衍生的肽和含有它们的疫苗
US10576097B2 (en) 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same

Also Published As

Publication number Publication date
US8623829B2 (en) 2014-01-07
SG193214A1 (en) 2013-09-30
US8759481B2 (en) 2014-06-24
EP2326718A1 (en) 2011-06-01
WO2010021111A1 (en) 2010-02-25
JP2012500001A (ja) 2012-01-05
US20110280898A1 (en) 2011-11-17
AU2009283762A1 (en) 2010-02-25
KR20110063456A (ko) 2011-06-10
MX2011001880A (es) 2011-03-29
US9067973B2 (en) 2015-06-30
EP2326718A4 (en) 2012-03-07
US20130189291A1 (en) 2013-07-25
US9284349B2 (en) 2016-03-15
US20140248300A1 (en) 2014-09-04
US20160200764A1 (en) 2016-07-14
US20140141027A1 (en) 2014-05-22
US20120321649A1 (en) 2012-12-20
CA2734515A1 (en) 2010-02-25
TW201008574A (en) 2010-03-01
US20100040641A1 (en) 2010-02-18
US8383590B2 (en) 2013-02-26
RU2011110504A (ru) 2012-09-27
IL211131A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2010021111A1 (en) Inhbb epitope peptides and vaccines containing the same
US8367799B2 (en) TEM8 peptides and vaccines comprising the same
CN102119171B (zh) Cdca1表位肽及包含它的疫苗
CN102186491B (zh) Hig2和urlc表位肽及包含它们的疫苗
US9675680B2 (en) MELK epitope peptides and vaccines containing the same
WO2009150835A1 (en) Iqgap3 epitope peptides and vaccines containing the same
WO2009150822A1 (en) Mybl2 epitope peptides and vaccines containing the same
HK1156341B (en) Melk epitope peptides and vaccines containing the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Application publication date: 20110914